Compare SMTI & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMTI | TCPC |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 337.3M |
| IPO Year | 2008 | 2006 |
| Metric | SMTI | TCPC |
|---|---|---|
| Price | $32.54 | $4.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $35.00 | $4.17 |
| AVG Volume (30 Days) | 95.7K | ★ 822.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 16.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $14.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $3.08 |
| 52 Week High | $35.52 | $6.25 |
| Indicator | SMTI | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 49.22 |
| Support Level | $30.40 | $4.07 |
| Resistance Level | $34.01 | $4.24 |
| Average True Range (ATR) | 1.00 | 0.13 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 75.84 | 31.03 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.